INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATYR

Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. regarding allegations of securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves claims that aTyr and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until December 8, 2025, to request to be appointed as Lead Plaintiff if they purchased aTyr securities during the Class Period [2]. Group 2: Company Performance - On September 15, 2025, aTyr announced that its EFZO-FIT study did not meet its primary endpoint, leading to a significant drop in stock price [4]. - Following the announcement, aTyr's stock price fell by $5.01 per share, or 83.17%, closing at $1.01 per share [5]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [6].